ACRV Acrivon Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1781174 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY9.6%
TTM EPS YoY14.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-74.1%
ROA-64.0%
ROIC (approx.)-104.8%
Asset turnover—
Leverage & solvency
Liabilities / assets17.5%
Debt / equity0.00x
Current ratio5.54x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $14.55M | $13.84M | $15.17M | $14.75M | $13.65M | $16.18M | $15.41M | $18.63M |
| SG&A expense | $3.97M | $4.82M | $4.74M | $5.37M | $6.04M | $6.47M | $6.25M | $6.32M |
| Operating income | -$18.52M | -$18.67M | -$19.90M | -$20.12M | -$19.69M | -$22.65M | -$21.66M | -$24.95M |
| Net income | -$17.90M | -$17.96M | -$19.04M | -$18.98M | -$18.23M | -$21.01M | -$19.68M | -$22.83M |
| EBITDA | -$18.12M | -$18.27M | -$19.52M | -$19.75M | -$19.39M | -$22.35M | -$21.35M | -$24.65M |
| EPS (basic) | -0.42 | -0.43 | -0.49 | — | -0.47 | -0.55 | -0.51 | — |
| EPS (diluted) | -0.42 | -0.43 | -0.49 | — | -0.47 | -0.55 | -0.51 | — |
| Weighted avg. shares (diluted) | 42.88M | 41.84M | 38.72M | — | 38.56M | 38.46M | 38.35M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $47.53M | $41.42M | $34.06M | $41.50M | $35.41M | $41.90M | $39.15M | $39.82M |
| Short-term investments | $30.22M | $48.54M | $63.67M | $77.08M | $93.85M | $95.53M | $110.48M | $139.66M |
| Current assets | $79.08M | $91.49M | $99.22M | $120.44M | $130.36M | $138.41M | $151.33M | $181.63M |
| PP&E, net | $3.83M | $4.25M | $4.65M | $4.89M | $5.19M | $5.07M | $4.68M | $4.47M |
| Total assets | $85.75M | $99.09M | $107.83M | $129.72M | $145.30M | $158.58M | $176.35M | $196.59M |
| Current liabilities | $14.28M | $11.45M | $11.05M | $15.66M | $14.89M | $13.43M | $13.55M | $17.21M |
| Total liabilities | $14.97M | $12.43M | $12.32M | $17.20M | $16.70M | $15.55M | $15.96M | $19.80M |
| Shareholders' equity | $70.77M | $86.67M | $95.52M | $112.52M | $128.60M | $143.04M | $160.39M | $176.79M |
| Shares outstanding | 42.91M | 42.85M | 38.75M | 31.65M | 31.55M | 31.45M | 31.35M | 31.23M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.38M | -$14.86M | -$20.54M | -$15.24M | -$12.28M | -$16.61M | -$19.54M | -$17.36M |
| Capital expenditure | $0 | $87,000 | $14,000 | $219,000 | $899,000 | $493,000 | $58,000 | $827,000 |
| Free cash flow | -$12.38M | -$14.95M | -$20.55M | -$15.46M | -$13.18M | -$17.10M | -$19.59M | -$18.19M |
| Investing cash flow | $18.50M | $14.95M | $13.13M | $21.52M | $5.91M | $19.45M | $19.21M | $14.41M |
| Financing cash flow | $0 | $7.27M | -$33,000 | -$192,000 | -$117,000 | -$97,000 | -$343,000 | -$647,000 |
| Depreciation & amortization | $400,000 | $400,000 | $383,000 | $361,000 | $300,000 | $300,000 | $311,000 | $303,000 |
| Stock-based compensation | $2.00M | $2.21M | $2.18M | $3.09M | $3.91M | $3.93M | $3.79M | $3.71M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.